Related Experiment Video
Updated: Aug 14, 2026
03:56
Operation Procedure and Precautions of Lingnan Fire-Needle Therapy in Osteoporosis Model Rats
Published on: April 26, 2024
An Inulin-Type Atractylodes Macrocephala Polysaccharide Alleviates Weightlessness-Induced Bone Loss in Association
Jinpeng Wang1, Rui Wang1, Fan Yang1
1School of Life Science and Technology, Harbin Institute of Technology, No. 2 Yi Kuang Street, Harbin 150001, China.
Nutrients
|August 13, 2026
Summary
Atractylodes macrocephala polysaccharide (AMP) 1-1 protects against weightlessness-induced bone loss (WIBL). It modulates the Nrf2 pathway, reduces oxidative stress, and improves bone health, offering a potential therapeutic strategy for spaceflight bone loss.
Area of Science:
- Spaceflight research
- Bone biology
- Pharmacology
Background:
- Prolonged microgravity exposure causes significant bone loss.
- Weightlessness-induced bone loss (WIBL) is a growing concern for long-duration space missions.
Purpose of the Study:
- To investigate the protective effects of Atractylodes macrocephala polysaccharide (AMP) 1-1 against weightlessness-induced bone loss (WIBL).
- To elucidate the underlying molecular mechanisms, focusing on the Nrf2 pathway.
Main Methods:
- Proteomic analysis to identify signaling pathways.
- Rat hindlimb suspension (HLS) model to simulate microgravity.
- Co-culture model of osteoblasts and RAW264.7 cells.
- Assessment of bone microarchitecture, biomechanical properties, and cellular differentiation.
Main Results:
- AMP 1-1 treatment improved bone microarchitecture and biomechanical properties in the HLS model.
- AMP 1-1 inhibited osteoclastogenesis and promoted osteoblastogenesis in vitro.
- AMP 1-1 activated the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, up-regulating antioxidant enzymes and reducing oxidative stress.
Conclusions:
- AMP 1-1 demonstrates significant protective effects against weightlessness-induced bone loss.
- The mechanism involves the modulation of the Nrf2 pathway and suppression of oxidative stress.
- AMP 1-1 represents a promising therapeutic candidate for preventing bone loss in microgravity environments.